{
    "2019-06-12": [
        [
            {
                "time": "2023-11-14",
                "original_text": "New Long-Term Data from Upadacitinib Phase 3 Studies in Rheumatoid Arthritis Including Results on Clinical Remission at 48 Weeks Presented at EULAR",
                "features": {
                    "keywords": [
                        "Upadacitinib",
                        "Phase 3",
                        "Rheumatoid Arthritis",
                        "Clinical Remission",
                        "EULAR"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-11-14",
                "original_text": "5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit",
                "features": {
                    "keywords": [
                        "Pipeline Drugs",
                        "Valuable",
                        "Stocks",
                        "Profit"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-11-14",
                "original_text": "10 Smart Dividend Stocks for the Rest of the Year",
                "features": {
                    "keywords": [
                        "Dividend Stocks",
                        "Smart",
                        "Year"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance",
                        "dividends"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}